{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:01:36Z","timestamp":1773226896940,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jvacx.2023.100388","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T01:22:00Z","timestamp":1695259320000},"page":"100388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Short-term safety of inactivated SARS-Cov-2 vaccines in Chinese patients with central nervous system inflammatory demyelinating diseases"],"prefix":"10.1016","volume":"15","author":[{"given":"Daidi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runze","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiarui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7709-3925","authenticated-orcid":false,"given":"Guoxun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8053-881X","authenticated-orcid":false,"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jvacx.2023.100388_b0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.jvacx.2023.100388_b0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.jvacx.2023.100388_b0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jvacx.2023.100388_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.jvacx.2023.100388_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jvacx.2023.100388_b0030","doi-asserted-by":"crossref","unstructured":"Olek MJ. Multiple sclerosis. Ann Intern Med 2021;174(6):Itc81\u201396.","DOI":"10.7326\/AITC202106150"},{"key":"10.1016\/j.jvacx.2023.100388_b0035","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.msard.2018.05.003","article-title":"Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder","volume":"23","author":"Mealy","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100388_b0040","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2041945","article-title":"Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis","volume":"18","author":"Etemadifar","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jvacx.2023.100388_b0045","doi-asserted-by":"crossref","unstructured":"Alonso R et al. Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America. Mult Scler J Exp Transl Clin 2021;7(4):20552173211061543.","DOI":"10.1177\/20552173211061543"},{"key":"10.1016\/j.jvacx.2023.100388_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103690","article-title":"Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis","volume":"59","author":"Ciampi","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jvacx.2023.100388_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103433","article-title":"Vaccination against SARS-CoV-2 in neuroinflammatory disease: early safety\/tolerability data","volume":"57","author":"Epstein","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jvacx.2023.100388_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103189","article-title":"Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases","volume":"55","author":"Lotan","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jvacx.2023.100388_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103424","article-title":"Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD","volume":"58","author":"Dinoto","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jvacx.2023.100388_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120155","article-title":"COVID-19 vaccination in patients with multiple sclerosis: safety and humoral efficacy of the third booster dose","volume":"434","author":"Dreyer-Alster","year":"2022","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100388_b0075","article-title":"Multiple sclerosis relapse following COVID-19 vaccination: a case report and literature review","volume":"14","author":"Kataria","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jvacx.2023.100388_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103321","article-title":"New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19","volume":"57","author":"Fragoso","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.jvacx.2023.100388_b0085","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200063","article-title":"Acute inflammatory diseases of the central nervous system after SARS-CoV-2 vaccination","volume":"10","author":"Francis","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jvacx.2023.100388_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2021.106839","article-title":"Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination","volume":"208","author":"Vogrig","year":"2021","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.jvacx.2023.100388_b0095","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.936574","article-title":"Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination","volume":"23","author":"Ahmad","year":"2022","journal-title":"Am J Case Rep"},{"issue":"5","key":"10.1016\/j.jvacx.2023.100388_b0100","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.radcr.2022.03.013","article-title":"Acute disseminated encephalomyelitis (ADEM) after SARS- CoV-2 vaccination: a case report","volume":"17","author":"Yazdanpanah","year":"2022","journal-title":"Radiol Case Rep"},{"key":"10.1016\/j.jvacx.2023.100388_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104003","article-title":"COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD","volume":"65","author":"Yeo","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jvacx.2023.100388_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577599","article-title":"Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients","volume":"356","author":"Kelly","year":"2021","journal-title":"J Neuroimmunol"},{"issue":"6","key":"10.1016\/j.jvacx.2023.100388_b0115","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis","volume":"78","author":"Salter","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jvacx.2023.100388_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.717111","article-title":"COVID-19 Vaccination attitudes with neuromyelitis optica spectrum disorders: vaccine hesitancy and coping style","volume":"12","author":"Xu","year":"2021","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.jvacx.2023.100388_b0125","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jvacx.2023.100388_b0130","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","author":"Hoftberger","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1016\/j.jvacx.2023.100388_b0135","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000382130","article-title":"Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review","volume":"44","author":"Kalincik","year":"2015","journal-title":"Neuroepidemiology"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136223001298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136223001298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T07:12:34Z","timestamp":1719990754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136223001298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":27,"alternative-id":["S2590136223001298"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2023.100388","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term safety of inactivated SARS-Cov-2 vaccines in Chinese patients with central nervous system inflammatory demyelinating diseases","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2023.100388","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100388"}}